Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
New devices are coming, but the real advances will involve combinations.
Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?